← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
3p Biotechnologies, Inc.
Prospect, KY
$4,026,707
Total funding
7
Grants
Funding over time
peak $1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,026,707 · 7
By mechanism
R41$2,008,856 · 5
R44$1,719,680 · 1
R43$298,171 · 1
Investigators at 3p Biotechnologies, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Exosomal Drug Delivery$1,000,000
R44 · FY2018 · CA
Exosomal Drug Delivery$719,680
R44 · FY2017 · CA
Targeted Exosomal Delivery of siRNA Therapeutics for Neuroinflammatory Diseases$506,451
R41 · FY2024 · AG
Trans Spinal Delivery of Targeted Exosomal Formulation of Curcuminoids to Treat AD$506,434
R41 · FY2025 · AG
Trans Spinal Delivery of a Targeted Nanoformulation of Curcuminoids to Treat AD$499,964
R41 · FY2024 · AG
Engineered Exosomes for Targeted Delivery of the CRISPR/Cas9 Genome-editor$264,507
R41 · FY2022 · OD
Sustained, target delivery for treatment of cervical pathologies$253,110
R43 · FY2012 · CA
Exosomal drug formulations$225,000
R41 · FY2014 · CA
Sustained, target delivery for treatment of cervical pathologies$45,061
R43 · FY2013 · CA
Trans Spinal Delivery of a Targeted Nanoformulation of Curcuminoids to Treat AD$6,500
R41 · FY2025 · AG